Yabao Pharmaceutical (Shanghai Securities: 600351) announced on July 7, 2014 that it had reached an authorized cooperation with Lawson Health Research Institute to develop and sell annexin A5, a product for the treatment of sepsis. At present, it has successfully completed the discovery and verification, and promoted the project to the preclinical development stage. The use of this product to treat sepsis was discovered by the team of Dr. Feng Qingping of Lawson Health Institute of Western University.
Under the terms of the agreement, Albo has the right to act as agent in the Chinese mainland, Taiwan and Hongkong for the discovery, development and sale of the project, while Lawson reserves the right to retain other markets. The financial terms have not been disclosed.
Dr. Wang Peng, R & D president of Yabao pharmaceutical, said: "Yabao pharmaceutical is very pleased to cooperate with Lawson Health Institute in Canada, which is committed to improving the lives of patients through medical discovery. The project has developed very smoothly. Because the indication is far from being met clinically, it shows its great potential as a new candidate drug. Yabao's further research and development of innovative products further proves Yabao's commitment to the use of new technologies The growing determination to cure major diseases.
Kirk brown, head of Lawson Health Institute and business development, said: "Our cooperation with Yabao has proved to be very effective and can promote the clinical development of annexin A5. We are deeply encouraged by the achievements so far. Lawson Health Research Institute is committed to bringing medical discoveries from the laboratory to the patient's bedside. Therefore, we are happy to cooperate with Chinese pharmaceutical companies and Yabao pharmaceutical, which has strong new drug R & D capability, in the field of sepsis The development of this promising new drug in severe cases, one of the major causes of death in the world. "
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) As a Chinese pharmaceutical enterprise, Yabao has perfect capabilities in drug development, production and commercialization in China. Recently, Yabao has adjusted its strategic development direction and aimed at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities, and the production of preparations and APIs meets the quality management of drug production CGMP requirements and passed the inspection of FDA and EU drug regulatory authorities respectively.
About Lawson Health Institute
Lawson Institute of health is a research institution under the London Health Science Center and St. Joseph health center. Together with Western University, Lawson Institute of health is committed to discovering more in-depth scientific knowledge to improve health care around the world. Worldiscoveries, a joint venture between Lawson Institute and rohbar Institute of health ® Responsible for the commercial operation of the Institute. Robal Health Institute is a Canadian technology transfer investment company with a branch in China.
请将简历发送至：